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Abstract
Background: Platinum-based chemotherapy has been a standard therapy for advanced non-small cell lung cancer
(NSCLC), but it has high toxicity. In China, Shenqi Fuzheng, a newly developed injection concocted from Chinese
medicinal herbs has been reported that may increase efficacy and reduce toxicity when combined with platinum-based
chemotherapy, but little is known about it outside of China. The aim of this study was to systematically review the existing
clinical evidence on Shenqi Fuzheng Injection(SFI) combined with platinum-based chemotherapy for advanced NSCLC.
Methods: Pubmed, Cochrane Library, EMBASE, CNKI, and CBM search were organized for all documents published,
in English and Chinese, until April 2010. The randomized controlled clinical trials were selected based on specific
criteria, in which a SFI plus platinum-based chemotherapy treatment group was compared with a platinum-based
chemotherapy control group for patients with advanced NSCLC. The quality of studies was assessed by modified
Jadad’s scale, and Revman 4.2 software was used for data syntheses and analyses.
Results: Twenty nine studies were included in this review based on our selection criteria. Of them, ten studies were
of high quality and the rest were of low quality, according to the modified Jadad scale. The meta-analysis showed
there was a statistically significant higher tumor response (RR, 1.19; 95% CI, 1.07 to 1.32; P = 0.001) and performance
status ((RR, 1.57; 95% CI, 1.45 to 1.70; P < 0.00001); but lower severe toxicity for WBC (RR, 0.37; 95% CI, 0.29 to 0.47; P <
0.00001), PLT (RR, 0.33; 95% CI, 0.21 to 0.52; P < 0.00001), HB (RR, 0.44; 95% CI, 0.30 to 0.66; P < 0.0001) and nausea
and vomiting (RR, 0.32; 95% CI, 0.22 to 0.47; P < 0.00001), when the SFI plus platinum-based chemotherapy treatment
group was compared with the platinum-based chemotherapy control group. Sensitivity analysis was restricted to
studies with the high quality, and the result was similar when the studies with low quality were excluded. Asymmetry
was observed in a funnel plot analysis, and Egger’s test also indicated an evidence of publication bias (P = 0.016).
Conclusions: SFI intervention appears to be useful to increase efficacy and reduce toxicity when combined with
platinum-based chemotherapy for advanced NSCLC, although this result needs to be further verified by more high-
quality trials.
Background
Lung cancer is the leading cause of cancer-related mor-
tality around the world, of which non-small cell lung can-
cer (NSCLC) accounts for approximately 85% [1].
Moreover, most NSCLC cases already reach stages III
and IV at the time of diagnosis indicating an advanced
and often inoperable stage of NSCLC. Platinum-based
chemotherapy has been a standard therapy and is widely
accepted for treatment of advanced NSCLC [1,2]. The
superiority of platinum-based chemotherapy over non-
platinum-based chemotherapy has been proved by many
randomized clinical trials. However, the resulting hematal
and gastrointestinal toxicity, such as leukopenia, throm-
bopenia, nausea, vomiting and so on, have also been
* Correspondence: zhanzheng_nj@163.com
† Contributed equally
4Institute of Basic Medical Science, Nanjing University of Traditional Chinese
Medicine, Nanjing, P.R China
Full list of author information is available at the end of the article
Dong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:137
http://www.jeccr.com/content/29/1/137
© 2010 Dong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.reported [3,4], which may seriously affect the patient’s
survival quality and curative effects. So, questions remain
on how to best reduce the toxicity and enhance the cura-
tive effect of platinum-based chemotherapy.
In China, to reduce the toxicity and enhance the cura-
tive effect of platinum-based chemotherapy, many tradi-
tional Chinese medicinal herbs have been widely used
combined with platinum-based chemotherapy for the
treatment of advanced NSCLC, and some researchers
[5,6] have found that combining Chinese medicinal
herbs with platinum-based chemotherapy for the treat-
ment of advanced NSCLC may improve survival, tumor
response, and performance status, as well as reduce che-
motherapy toxicity.
Shenqi Fuzheng is a newly developed injection con-
cocted from two kinds of Chinese medicinal herbs: Radix
Astragali (root of astragalus; Chinese name: huangqi) and
Radix Codonopsis (root of Codonopsis pilosula; Chinese
name: dangshen)[7,8], approved by the State Food and
Drug Administration of the People’s Republic of China in
1999 primarily as an antitumor injection to be manufac-
tured and marketed in China [9,10]. Currently, there are
many published trials about Shenqi Fuzheng Injection(SFI)
combined with platinum-based chemotherapy for treat-
ment of advanced NSCLC, some of which have shown
that SFI may play an important role in the treatment of
advanced NSCLC, could improve tumor response, perfor-
mance status and reduce the toxicity of standard plati-
num-based chemotherapy. However, little is known about
it outside of China, and there has not been a systematic
evaluation until now. This paper presents a systematic
review in an effort to clarify whether SFI in combination
with platinum-based chemotherapy for advanced NSCLC
really increases the efficacy and decreases the toxicity.
Methods
Search strategy
According to guidelines from the Cochrane collabora-
tion [11], PubMed (1966 to April 2010); Cochrane
Library (1988 to April 2010); EMBASE (1974 to April
2010); and Cochrane Central Register of Controlled
Trials (1966 to April 2010); CBM (1978 to April 2010);
CNKI(1984 to April 2010) were organized for search,
and the following keywords were used: non-small-cell
lung cancer, platinum-based chemotherapy, Shenqi Fuz-
heng injection, randomized controlled trials and multi-
ple synonyms for each term. The publication languages
were restricted to Chinese and English.
Studies selection
Trials were included if they were randomized controlled
trials comparing a SFI plus platinum-based chemother-
apy treatment group with a platinum-based chemother-
apy control group for patients with advanced NSCLC.
Moreover, the reported data must have at least one of
following outcomes: objective tumor response (the
4-point WHO scale [12] was adopted), performance sta-
tus (the Karnofsky performance scale [13] was used and
performance status was divided into 3 grades using a
10-point change as the cutoff), and toxicity (the 5-point
WHO scale [12] was used), and the reported data also
needed to have sufficient detail to permit the calculation
of the risk ratios and it’s 95% CIs for each outcome.
Data expressed as medians were not included in this
meta-analysis, and the duplicates, case series, and case
reports were also excluded.
Data extraction
All data on patient characteristics, treatment details, and
clinical outcomes were independently abstracted and
duplicated by two investigators (Ju Dong, Shi-Yue Su)
using a standardized data collection form. Disagree-
ments on study inclusion or data extraction were
resolved by consensus of all coauthors. The outcome
measures extracted were: objective tumor response,
improved or stabilized performance status, and severe
chemotherapy toxicity.
Statistical analysis
Meta-analysis was done with Review Manager 4.2 (The
Cochrane Collaboration, Oxford, UK) [11]. Relative
ratio (RR) and 95% confidence intervals (CI) were calcu-
lated, hypothesis of homogeneity was not rejected, the
fixed-effects model was used to calculate the summary
r e l a t i v er a t i o( R R ) ,a n dt h e9 5 %C I .O t h e r w i s e ,ar a n -
dom-effects model was used [14]. In this meta-analysis,
three kind of following outcomes were calculated and
analyzed appropriately.
1. Objective tumor response
The rate of tumor response was calculated as the number
of patients experiencing complete response and partial
response divided by the total number of patients (com-
plete response plus partial response plus no change plus
progressive disease) in each group, The RR of tumor
response was calculated as the rate of tumor response in
the SFI combined with platinum-based chemotherapy
treatment group divided by that in the platinum-based
chemotherapy control group. Thus, a RR of more than 1
favors the SFI combined with platinum-based che-
motherapy treatment group. This method has been
recommended by Sutton et al [15].
2. Improved or stable performance status
This is similar to the approach of Michael et al [5]. The
rate of improved or stable performance status was calcu-
lated as the proportion of improved or stable perfor-
mance status (>10-point increase plus no change) divided
by the total (>10-point increase, plus no change, plus
>10-point decrease). The RR of improved or stable
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or stable performance status in the SFI combined with
platinum-based chemotherapy treatment group, divided
by this proportion in the platinum-based chemotherapy
control group. Thus, a RR of more than 1 favors the SFI
combined with platinum-based chemotherapy treatment
group.
3. Severe chemotherapy toxicity
Using the approach of Delbaldo et al [16], the rate of
severe chemotherapy toxicity was defined as the number
of patients experiencing severe toxicity (WHO grades 3
and 4) divided by the total number of patients (WHO
grades 0, 1, 2, 3 and 4) in each group. The RR of severe
chemotherapy toxicity was analyzed as the proportion of
severe toxicity in the SFI combined with platinum-based
chemotherapy treatment group divided by this propor-
tion in the platinum-based chemotherapy control group.
Thus, a RR of less than 1 favors the SFI combined with
platinum-based chemotherapy treatment group.
Study quality evaluation
Two reviewers (Ju Dong, Shi-Yue Su) independently
graded each RCT/CCT using the modified Jadad scale[17].
The modified Jadad scale is an eight-item scale designed
to assess randomization, blinding, withdrawals/dropouts,
inclusion/exclusion criteria, adverse effects, and statistical
analysis (table 1). The score for each article can range
from 0 (lowest quality) to 8 (highest quality). Scores of 4-8
represent good to excellent (high quality) and 0 to 3 poor
or low quality.
Sensitivity analysis
Sensitivity analysis was used to assess how robust the
results are to uncertain decisions or assumption about
the data and the methods that were used [18]. To analyze
the sensitivity of our study, some studies were excluded
because they were of low quality (had a quality score of 3
or under 3) and thus may weaken the conclusions.
Publication bias analysis
For the purposes of assessing the publication bias of this
study, a funnel plot based on studies with data on objec-
tive tumor response (as this was the outcome with most
studies included in meta-analysis) was graphed and
Egger’s test[19] was also performed.
Results
Study characteristics and quality
Twenty nine studies [20-48] were included in this
review based on our selection criteria, encompassing
2,062 patients. A total of thirty studies were excluded
due to lack of inclusion criteria, missing data and multi-
ple publications. All included trials were published after
2004, and vinorelbine plus cisplatin (NP) was the most
common chemotherapy regimen (19/29,65.5%), and the
remainder included paclitaxel plus cisplatin (TP), gemci-
tabine plus cisplatin (GP), and docetaxel plus cisplatin
(DC). Of the 29 trials included in meta-analysis,24 trials
were reported as RCTs, and 5 trials didn’td e s c r i b e
clearly the methods of grouping. Of the 24 trials claimed
to be RCTs, the randomization procedure was described
clearly and was true in only 5 trials(random digital table
was adopted), 15 trials stated that subjects were “rando-
mized” without describing the randomization method or
procedures, 4 trials stated that methods that were not
truly randomized were used. According to the modified
Jadad scale, 10 studies were of high quality, with a qual-
ity score of 4 or above 4, and the rest were of low qual-
ity, with a quality score of 3 or under 3. Characteristics
and quality of all included studies are presented in table
2.
The result of meta-analysis for Objective tumor response
In the 29 included trials, the objective tumor response
was reported by 27 trials [21-36,38-48], which included
1,849 patients. Meta-analysis showed there was a statis-
tically significant higher tumor response rate (RR, 1.19;
95% CI, 1.07 to 1.32; P = 0.001; Figure 1) in the SFI
combined with platinum-based chemotherapy treatment
group compared with the platinum-based chemotherapy
control group, which meant the significant 19% increase
in the RR for the response rate was attributable to the
SFI combined with platinum-based chemotherapy treat-
ment group. Because heterogeneity may not lie in the
different studies(P = 0.98) in this meta-analysis, the
fixed-effect model was used.
The result of meta-analysis for Performance status
The rates of improved or stable performance status were
reported in 20 trials [20,21,23,25,26,28,30,31,33,36-
43,45-47], which included 1336 patients. Meta-analysis
showed there was a statistically significant higher rate of
improved or stable performance status (RR, 1.57; 95%
CI, 1.45 to 1.70; P < 0.00001; Figure 2) when the SFI
combined with platinum-based chemotherapy treatment
group was compared with the platinum-based che-
motherapy control group, which meant the significant
57% increase in the RR for the rate of improved or
stable performance status was attributable to the SFI
combined with platinum-based chemotherapy treatment
group. For the same reason as objective tumor response,
the fixed-effect model was performed in this meta-
analysis.
The result of meta-analysis for grade 3 or 4 WBC, PLT,
HB, Nausea and Vomiting Toxicity
In all included studies, 20 trials [20-25,27-29,32,34-36,
38,40-42,44,45,48] reported the number of patients with
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[20-25,27-29,32,34-36,40-42,44,45] reported the number
of patients with grade 3 or 4 platelet (PLT) toxicity, 15
trials [20,22-25,28,29,32,34-36,41,42,44,45] reported the
number of patients with grade 3 or 4 hemoglobin (HB)
toxicity and 14 trials [20,22-24,27-29,35,36,38,40-42,45]
reported the number of patients with grade 3 or 4 nausea
and vomiting. The rate of severe chemotherapy toxicity
was calculated for WBC, PLT, HB, nausea and vomiting,
and then meta-analyses were performed. As shown in
Figures, the results indicated there was statistically signif-
icant lower severe toxicity for WBC (RR, 0.37; 95% CI,
0.29 to 0.47; P < 0.00001; Figure 3), PLT (RR, 0.33; 95%
CI, 0.21 to 0.52; P < 0.00001; Figure 4), HB (RR, 0.44;
95% CI, 0.30 to 0.66; P < 0.0001; Figure 5) and nausea
and vomiting (RR, 0.32; 95% CI, 0.22 to 0.47; P <
0.00001; Figure 6) when the SFI plus platinum-based che-
motherapy treatment group was compared with the plati-
num-based chemotherapy control group.
The result of sensitivity analysis
The sensitivity analysis revealed that with low quality
studies excluded, the summary RR and 95% CIs for
above outcomes were still similar to the results before
they were excluded (table 3), which indicates that the
results of our study are reliable and believable.
The result of publication bias analysis
Figure 7 is the funnel plot based on studies with data on
objective tumor response, which is asymmetrical, and
indicates that publication bias may have existed in our
study. The result of Egger’s test also suggested an evi-
dence of publication bias (P = 0.016).
Discussion
In medicine, systematic reviews and meta-analysis form
the core of a movement to ensure that medical treat-
ments are based on the best available empirical data. One
important advantage for meta-analysis is that it can
enable the user to perform statistical synthesis and then
it can be used to enhance the statistical power to obtain a
more accurate conclusion [49]. Thus, to systematically
evaluate whether SFI increases the efficacy and decreases
the toxicity when combined with platinum-based che-
motherapy for advanced NSCLC, the authors conducted
a systematic review. The results suggested that SFI inter-
vention may enhance tumor response, improve perfor-
mance status, and reduce chemotherapy toxicity, when
compared with platinum-based chemotherapy alone.
This is the first systematic review of SFI for advanced
NSCLC and the results can provide important references
about how to reduce toxicity and enhance the curative
effect of platinum-based chemotherapy. In China, it is
common to use SFI to treat advanced NSCLC, but no
relevant articles or evaluations have been published in
the English medical journals, hence reducing its world-
wide validity. This study may prove useful for supple-
menting the evidence for the use of SFI in the treatment
of advanced NSCLC.
Shenqi Fuzheng Injection is concocted from Radix
Astragali(huangqi) and Radix Codonopsis(dangshen).
These two kind of Chinese medicinal herbs have been
Table 1 The modified Jadad scale
Eight-item of the modified Jadad scale Score
Was the study described as randomized? Yes +1
No 0
Was the method of randomization appropriate? Yes +1
No -1
Not described 0
Was the study described as blinding?
a Yes +1
No 0
Was the method of blinding appropriate? Yes +1
No -1
Not described 0
Was there a description of withdrawals and dropouts? Yes +1
No 0
Was there a clear description of the inclusion/exclusion criteria? Yes +1
No 0
Was the method used to assess adverse effects described? Yes +1
No 0
Was the methods of statistical analysis described? Yes +1
No 0
a: double-blind got 1 score, single-blind got 0.5 score.
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medicines for many years. Of them, Radix Astragali is
usually used as an immunomodulating agent in the
treatment of immunodeficiency diseases and to allevi-
ate the adverse effects of chemotherapeutic drugs
[50,51]. Radix Codonopsis is usually used to treat dys-
pepsia, fatigue, bronchitis, cough, inflammation and so
on, and its pharmacological activities such as antifati-
gue and immunomodulatory activities were also
reported[52]. SFI is developed from Radix Astragali
and Codonopsis, which suggests that its effect in the
treatment of NSCLC may be related with the above
pharmacological activities of Radix Astragali and
Codonopsis. However, what are the specific immunolo-
gical and cytotoxic mechanisms? what are main
effective components? Do the interactions between
m e d i c i n e so rc o m p o n e n t se x i s t ?T h e s eq u e s t i o n sa r e
not clear and require further investigation.
This systematic review also has limitations. First, allo-
cation concealment and blinding were not described in
all included trials, which may result in the emergence of
bias, and the overestimation of the efficacy of the treat-
ment group. Second, much of the data on the patients’
survival was not reported in the included studies, thus
the influence that SFI combined with platinum-based
chemotherapy had on survival could not be analyzed by
this systematic review. Third, funnel plot and Egger’s test
suggested publication bias may exist. Given above rea-
sons, the evidence from this study may be insufficient,
and should be carefully disseminated to the medical
Table 2 Study characteristics and quality
Studies (Author) Year Chemotherapy
regimen
a
Number (T/C) Type of Assessable Outcomes Jadad Scores
b
treatment control
Hao XL[20] 2008 NP+SFI NP 60/68 WBC/HB/PLT/nausea and vomiting toxicity, KPS 3
Wang K[21] 2007 NP+SFI NP 18/18 tumor response, WBC/PLT toxicity, KPS 3
Kang GY[22] 2006 NP+SFI NP 36/36 tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS 2
Gong ZM[23] 2008 NP+SFI NP 33/32 tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS 2
Wang XY[24] 2007 NP+SFI NP 35/34 tumor response, WBC/PLT/HB/nausea and vomiting toxicity, 4
Wang YZ[25] 2007 NP+SFI NP 28/27 tumor response, KPS, WBC/PLT/HB toxicity 3
Li TW[26] 2009 NP+SFI NP 36/33 tumor response, the KPS 4
Li Y[27] 2007 NP+SFI NP 44/43 tumor response, WBC/PLT/nausea and vomiting toxicity, 4
Lv J[28] 2008 NP+SFI NP 40/40 tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS 4
Zhao ZY[29] 2007 NP+SFI NP 35/34 tumor response, WBC/PLT/HB nausea and vomiting toxicity, 4
Geng L[30] 2004 NP+SFI NP 25/15 tumor response, KPS 2
Yu QZ[31] 2007 NP+SFI NP 30/32 tumor response, KPS 4
Liu CL[32] 2004 NP+SFI NP 60/60 tumor response, WBC/PLT/HB toxicity 2
Liu PH[33] 2007 NP+SFI NP 30/30 tumor response, KPS 1
Pan YK[34] 2008 NP+SFI NP 45/45 tumor response, WBC/PLT/HB toxicity 2
Zheng JH[35] 2009 NP+SFI NP 42/42 tumor response, WBC/PLT/HB/nausea and vomiting toxicity 4
Miao SR[36] 2010 NP+SFI NP 38/41 tumor response, the KPS, WBC/PLT/nausea and vomiting toxicity 3
Li YQ[37] 2010 NP+SFI NP 43/42 KPS 5
Geng D[38] 2007 NP+SFI NP 42/26 tumor response, WBC/the nausea and vomiting toxicity 2
Zou Y[39] 2005 TP+SFI TP 24/24 tumor response, KPS 3
Luo SZ[40] 2006 TP+SFI TP 25/25 tumor response, KPS, WBC/PLT/nausea and vomiting toxicity 2
Luo SW[41] 2007 TP+SFI TP 30/30 tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS 2
Zhang FL[42] 2008 TP+SFI TP 30/30 tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS 3
Zhao YX[43] 2009 TP+SFI TP 40/40 tumor response, KPS 2
Yu F[44] 2007 DC+SFI DC 30/30 tumor response, WBC/PLT/HB toxicity 4
He WJ[45] 2008 GP+SFI GP 35/35 tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS 3
Liang K[46] 2010 GP+SFI GP 39/37 tumor response, KPS, 2
Chen J[47] 2007 TP/NP+SFI TP/NP 41/39 tumor response, KPS 2
Wu L[48] 2004 TP/NP+SFI TP/NP 30/30 tumor response, WBC toxicity 5
Abbreviations: SFI, shenqi fuzheng injection; NP, vinorelbine, cisplatin; TP, paclitaxel, carboplatin; DC, docetaxel cisplatin; GP, gemcitabine cisplatin;T/C, treatment
group/control group; KPS, Karnofsky Performance status; WBC, white blood cell; PLT, platelet; HB, hemoglobin;
a: all patients included in studies in both groups received systemic chemotherapy therapy, and no patients received surgery and radiation, The only difference
between the two groups was whether they received SFI.
b: modified Jadad scale was used.
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Figure 2 Forest-plot of stabled/improved Kamofsky performance status.
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expensive to carry out clinical trials on advanced NSCLC
patients and large, placebo-controlled, double-blind stu-
dies are almost impossible. Therefore, trials with above
questions may exist in many countries and may be
permitted to some extent, but still provide helpful infor-
mation for clinical practice and drug development. Now
it has been increasingly recognized that Western medi-
cine may not be the answer for the treatment of all dis-
eases and sometimes alternative medicines or treatment
Figure 3 Forest-plot of grade 3 or 4 WBC toxicity.
Figure 4 Forest-plot of grade 3 or 4 PLT toxicity.
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kind of traditional Chinese medicine, the results of this
systematic review suggested it may play an important
role in the treatment of advanced NSCLC.
Conclusions
In conclusion, in this systematic review evidence was
found that SFI intervention m a yi n c r e a s et h ee f f i c a c y
and reduce the toxicity when combined with platinum-
based chemotherapy for advanced NSCLC, which would
provide important references about how to reduce toxi-
city and enhance the curative effect of platinum-based
chemotherapy for advanced NSCLC. However, limita-
tions remain and the results needs to be further verified
by more high-quality trials.
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